LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations

Published:2012-06 Issue: Volume:77 Page:S25-S26
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Schuler Martin,Yang James Chih-Hsin,Yamamoto Nobuyuki,O’Byrne Ken,Hirsh Vera,Mok Tony,Massey Dan,Zazulina Victoria,Shahidi Mehdi,Sequist Lecia

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC;Exploration of Targeted Anti-tumor Therapy;2024-07-19

2. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China;Pharmacology;2021

3. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice;Pharmacological Research;2020-11

4. CT Radiomics in Predicting EGFR Mutation in Non-small Cell Lung Cancer: A Single Institutional Study;Frontiers in Oncology;2020-10-07

5. Prognostic value of EGFR 19‑del and 21‑L858R mutations in patients with non‑small cell lung cancer;Oncology Letters;2019-08-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP